CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
Vorico Injection 200mg(Voriconazole) +1 moredrug
Likely dose
Vorico Injection 200mg(Voriconazole)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02631954
NCT02631954Phase 1Completed
CompareCT.gov

Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers

Chong Kun Dang Pharmaceutical·interventional·Posted Dec 16, 2015·Updated Mar 18, 2020

In Brief

A Phase 1 clinical trial evaluating Vorico Injection 200mg(Voriconazole) and Vfend®(Voriconazole) IV 200mg for Aspergillus Infections and 2 related conditions. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAspergillus Infections, Candida Infections, Fungal Infections
CountriesSouth Korea
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 16, 2015
Enrollment StartSep 1, 2015
Primary CompletionOct 1, 2015
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 10.5 years ago

Interventions

Vorico Injection 200mg(Voriconazole)drug

Vorico Injection 200mg(Voriconazole) to administered intravenously once

Vfend®(Voriconazole) IV 200mgdrug

Vfend®(Voriconazole) IV 200mg to administered intravenously once